Biogen (BIIB) Tops Q1 EPS by $1.40
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
SunTrust Defends Biogen (BIIB); 'Buy on Weakness'
April 22, 2020 10:12 AM EDTSunTrust analyst Robyn Karnauskas reiterated a Buy rating and $360.00 price target on Biogen (NASDAQ: BIIB), telling clients to 'buy on weakness'
Karnauskas notes the company updated their Alzheimer's Disease (AD) filing timelines from early 2020 to a rolling BLA, with completion by 3Q20,... More
Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out
April 22, 2020 7:50 AM EDTBiogen (NASDAQ: BIIB) is down 6% in pre-open trading despite strong results as the company said it stated submitting modules for aducanumab BLA and expects the U.S. filing in the third quarter, which pushes out the launch timelines.
... More